@article{870ee385466745968b29cbc743920b4c,
title = "Migraine research comes of age in the 21st century",
author = "Moskowitz, {Michael A.} and Dodick, {David W.} and Scher, {Ann I.} and {van den Maagdenberg}, {Arn M.J.M.}",
note = "Funding Information: MAM declares no competing interests. DWD reports the following financial or non-financial interests unrelated to this manuscript: consulting for Amgen, Atria Health, CapiThera, Cerecin, Cooltech, Ceruvia Lifesciences, Ctrl M, Allergan, Biohaven, GSK, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Nocira, Perfood, Praxis, AYYA Biosciences, Revance; honoraria from Vector psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin, Medlogix Communications, MJH Lifesciences, Miller Medical Communications, WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press; research support from the US Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute; holding stock options, shares, patents, or board directorship for Aural analytics (options), ExSano (options), Man and Science (options), Healint (options), Theranica (options), Second Opinion/Mobile Health (options), Epien (options and board) Nocira (options), Matterhorn (shares and board), Ontologics (shares and board), King-Devick Technologies (options and board), Precon Health (options and board), AYYA Biosciences (options), Atria Health (options); holding a patent 17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis (non-royalty bearing) and a patent application submitted for Synaquell (Precon Health). AIS receives research support from Eli Lilly and company. AMJMvdM reports support from Schedule 1 Therapeutics, Praxis Precision Medicine, and AbbVie. The views expressed are those of the authors and should not be construed to represent the positions of the Uniformed Services University or the Department of Defense. All authors contributed equally.",
year = "2022",
month = nov,
doi = "10.1016/S1474-4422(22)00398-2",
language = "English",
volume = "21",
pages = "955--958",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Elsevier Ltd",
number = "11",
}